Business
Theralase Granted United States Patent to Destroy Cancer Cells with X-Ray Activated Photo Dynamic Compounds
TORONTO, ONTRAIO / ACCESSWIRE / March 4, 2019 / Theralase Technologies Inc. (" Theralase
...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase Granted United States Patent to Destroy Cancer Cells with X-Ray Activated Photo Dynamic CompoundsTORONTO, ONTRAIO / ACCESSWIRE / March 4, 2019 / Theralase Technologies Inc. (\"Theralase®\" or the \"Company\") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (\"PDCs\") and their associated drug formulations intended to safely and effectively destroy various cancers, announced today that it has been granted allowance for a United States patent to issue later this year for destroying cancer cells with X-ray activated PDCs.The new patent to issue later this year is entitled, \"Photodynamic Compounds and Methods for Activating Them Using Ionizing Radiation and/or Other Electromagnetic Radiation for Therapy and/or Diagnostics\"Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer of Theralase® and the lead inventor of the technology stated that, \"In 2019, the Company plans to commence a Phase II Non-Muscle Invasive Bladder Cancer (\"NMIBC\") clinical study, which if successful may lead to commercialization of this technology in Canada, the United States and the European Union. On top of this clinical study, this patent opens up new possibilities with far reaching oncological treatment implications, including: targeting cancers that are difficult, if not impossible to reach with surgery or conventional laser light sources, such as Glio Blastoma Multiforme (\"GBM\"), a deadly form of brain cancer, Non-Small Cell Lung Cancer (\"NSCLC\") or other deep tissue related cancers, such as soft tissue sarcomas. The Company is investigating evaluating Rutherrin® (TLD-1433 PDC combined with transferrin) in combination with X-ray in a Phase Ib clinical study for GBM. This patent, when issued, will validate the proprietary position of the Company's Anti-Cancer Technology (\"ACT\") for the US oncology market, demonstrating Theralase's strong commitment to the development of a comprehensive intellectual property portfolio, attractive to a pharmaceutical partner.\"About Rutherrin® On the surface of all cells, there are carrier proteins known as Transferrin Receptors (\"TfRs\"). These TfR's main role is to link with the glycoprotein Transferrin (\"Tf\") to enable the cell to absorb iron, an essential element requir...